Otis’s Overlooked Elevator Moat Is Quietly Getting Cheaper
Otis Worldwide’s stock is down roughly 15% year-to-date, but the business generating over 90% of its profits — servicing the 2.5 million elevators it already has in the field — just got structurally more valuable. In April, Finland’s Kone agreed to buy Germany’s TK Elevator for nearly $35 billion, a deal that would shrink the industry from four major players to three. If it clears regulatory scrutiny, Otis inherits a more rational, less price-competitive market for the recurring service contracts that actually make it money.
That’s the part Wall Street’s AI-chasing capital seems to be missing. Otis’s new-equipment business — installing elevators — runs at a thin 4.8% operating margin; nobody gets rich building elevators. The real engine is the 20-year-plus service tail that follows each installation: maintenance, repairs, and eventual modernization, which together produced a 25.5% margin in 2025. The company services elevators in more than 200 countries and grew service sales 11% year-over-year in its most recent quarter, even as retention — the renewal rate on those contracts — hasn’t yet fully recovered from a slump that started in 2025. Otis is plowing an incremental $50 million into fixing that in 2026, betting that fewer outages mean happier, stickier customers. Renewals are somewhat automatic if no one is unhappy, as one analyst put it.
None of this is glamorous. There is no AI angle, no chip shortage narrative, no 40% quarterly revenue growth. What Otis offers instead is what patient capital has always prized: a toll-booth business with decadeslong tailwinds from urbanization, an aging population needing mobility solutions, and infrastructure modernization that is not going away regardless of what happens with data center capex. Management describes this as a decadelong opportunity, not a quarterly trade.
So what for long-term investors: a 15% pullback in a company where roughly 90 cents of every profit dollar comes from recurring, multi-decade service contracts — with a looming industry consolidation that could reduce competitive intensity — is exactly the kind of boring-is-beautiful mispricing patient capital should be watching. The retention numbers over the next two quarters will tell you whether the moat is widening or just holding steady.
